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Infection (2015), http://dx.doi.org/1Abstract Background/Purpose: To compare the clinical efficacy and safety of nemonoxacin
with levofloxacin in treating community-acquired pneumonia (CAP) in a Phase II clinical trial.
Methods: One hundred ninety-two patients with CAP were randomized to receive oral nemo-
noxacin (500 mg or 750 mg) or levofloxacin (500 mg) once daily for 7e10 days. Clinical and
bacteriological responses were determined at the test of cure (TOC) visit in the full analysis
set (FAS).
Results: The clinical cure rate of nemonoxacin (500 mg), nemonoxacin (750 mg), and levoflox-
acin (500 mg) was 93.3%, 87.3%, and 88.5%, respectively, in the FAS (n Z 168), and 93.0%,
93.9%, and 88.9%, respectively in the per protocol set (nZ 152). At the TOC visit, nemonoxacin
at 500 mg and 750 mg was proven to be noninferior to levofloxacin at 500 mg in the FAS in terms
of clinical efficacy. The overall bacteriological success rate was 83.3% in both nemonoxacin
groups and 80.0% in the levofloxacin 500 mg group in the bacteriological FAS. The comprehen-
sive efficacy rate was comparable among the three groups (87.5% for the nemonoxacin 500 mg
group, 93.8% for the nemonoxacin 750 mg group, and 81.3% for the levofloxacin 500 mg group).
Most drug-related adverse events were mild and transient, mainly gastrointestinal symptoms
such as nausea and vomiting, transient neutropenia, and elevated liver enzymes. No drug-
related serious adverse events occurred.
Conclusion: Either 500 mg or 750 mg of oral nemonoxacin taken once daily for 7e10 days
demonstrated high clinical and bacteriological success rates in Chinese adult patients with
CAP. Nemonoxacin at 500 mg once daily for 7e10 days is recommended for future Phase III clin-
ical trials.
ClinicalTrials.gov identifier: NCT01537250.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Community-acquired pneumonia (CAP) is a common lower
respiratory tract infection with high morbidity and mortal-
ity.1,2 Community-acquired pneumonia can be caused by a
variety of pathogens such as Streptococcus pneumoniae,
Haemophilus influenza, and Mycoplasma pneumoniae.3,4 In
recent years the emergence and spread of antibiotic-
resistant pathogens has become big challenge in the clinical
management of CAP. In 2013, the China net (CHINET)
of bacterial resistance surveillance data showed that the
prevalence of penicillin-intermediate S. pneumoniae (PISP)Y, et al., A randomized, double-b
xacin in the treatment of commun
0.1016/j.jmii.2015.09.005andpenicillin-resistant S. pneumoniae (PRSP) increased up to
32.9% (PISP 11.6%; PRSP, 21.3%) and 9.4% (PISP, 5.4%; PRSP,
4.0%) in isolates from children and adults, respectively.5
Surveillance studies also showed a high prevalence of S.
pneumoniae strains that were resistant to erythromycin or
clindamycin, especially in PISP and PRSP strains.6 Quinolone
drugs are active against CAP pathogens such as penicillin
nonsusceptible S. pneumoniae and are recommended for
adult CAP.2
Nemonoxacin, a nonfluorinated quinolone targeting DNA
gyrase and topoisomerase IV, has broad-spectrum activity
against gram-positive pathogens and some atypicallind, multicenter Phase II study comparing the efficacy and safety
ity-acquired pneumonia, Journal of Microbiology, Immunology and
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niae and methicillin-resistant Staphylococcus aureus
(MRSA).7e11 Nemonoxacin is also active against gram-
negative bacteria such as H. influenzae and Klebsiella
pneumoniae.7,11 One study in mice showed that the effi-
cacy of nemonoxacin was better than that of levofloxacin in
treating gram-positive bacterial infections such as infection
by PRSP and MRSA.12
Previous Phase I studies have been conducted in
healthy volunteers in the United States and China to
examine the safety and clinical pharmacokinetics (PK) of
nemonoxacin after single and multiple oral doses.6,13,14
After oral administration, nemonoxacin is absorbed
rapidly and well tolerated. Within 1e2 hours after oral
administration, nemonoxacin attains peak plasma con-
centration (Cmax), and exhibits a linear PK profile within a
dose range of 250e750 mg. The Cmax [i.e., area under the
curve from 0 to infinity (AUC0-N)] was dose-dependent
after multiple doses. Nemonoxacin is excreted primarily
in urine. Approximately 60e70% of the drug was elimi-
nated within 72 hours in its unchanged form. The elimi-
nation half-life is 9e16 hours. There is no accumulation
after administering it for 10 consecutive days.6,13
In 2010, Van Rensburg et al15 reported a clinical trial
that investigated the efficacy and safety of nemonoxacin,
compared to that of levofloxacin in CAP outpatients.15 They
found that nemonoxacin was noninferior to levofloxacin in
either the evaluable intent-to-treat population or clinical
per protocol (PPc) population. Both treatments were well
tolerated without any serious drug-related adverse
reactions.
We conducted a randomized, double-blind, multicenter
clinical trial to evaluate the safety and efficacy of 500 mg
and 750 mg oral doses of nemonoxacin, compared to
500 mg levofloxacin, administered once daily for
7e10 days in treating patients with CAP in the Chinese
population.
Methods
Study design
A Phase II, randomized, double-blind, double dummy,
multicenter study was designed to compare the efficacy
and safety of oral nemonoxacin with that of levofloxacin in
Chinese adult patients with CAP. The primary objective of
this study was to demonstrate the noninferiority of nem-
onoxacin versus levofloxacin with regard to safety and
clinical efficacy. The study was conducted in compliance
with good clinical practice guidelines and the Declaration
of Helsinki. The study protocol was approved by the Ethics
Committees of all participating institutions. All patients
provided written informed consent before enrollment in
the study.
Study treatments
Eligible patients were randomized from August 2009 to
August 2010 to one of three treatment groups in a 1:1:1
ratio to receive an oral dose of 500 mg or 750 mg nem-
onoxacin (TaiGen Biotechnology Co., Ltd., Taipei, Taiwan)Please cite this article in press as: Liu Y, et al., A randomized, double-b
of oral nemonoxacin with oral levofloxacin in the treatment of commun
Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.09.005or 500 mg levofloxacin and a matched placebo. The drugs
were administered once daily for 7e10 days. Immediately
after enrollment, the first dose was administered on site in
the clinic. For all subsequent doses, the patients took their
study drug in the every morning.
Inclusion criteria
Male and female patients were eligible if they were
18e70 years old, had a body weight within the range of
40e100 kg, had a body mass index (BMI) of  18 kg/m2, and
had a diagnosis of mild to moderate CAP. The diagnosis was
based on two or more of the following clinical manifesta-
tions and a chest radiograph showing new lobar or multi-
lobar infiltrates consistent with CAP within 48 hours.
Clinical manifestations included (1) productive cough with
purulent sputum or deterioration of existing respiratory
symptoms; (2) fever (i.e., oral temperature  37.3C); (3)
evidence of pulmonary consolidation and/or rales; (4) pe-
ripheral white blood cell count of > 10  109 cells/L
or < 4  109 cells/L or a neutrophil level > 70%. Criterion
(2) or (4) had to be present when patients were enrolled.
Exclusion criteria
Pregnant or lactating women were excluded from the
study. Individuals were also excluded if they had any of
the following conditions: lung diseases such as active
tuberculosis, bronchiectasis, lung abscess, aspiration
pneumonia, lung malignancies, noninfectious interstitial
lung disease, pulmonary edema, atelectasis, pulmonary
embolism, pulmonary eosinophilia or pulmonary vasculitis,
nosocomial pneumonia; history of hypersensitivity or
allergic reaction to any quinolone drug; history of epi-
lepsy, mental disorders, or other diseases of the central
nervous system; renal failure; liver dysfunction; malab-
sorption syndrome or other gastrointestinal disease; im-
munodeficiency status such as HIV infection, CD4þ count
of <200/mm3 or neutropenia, or blood or solid organ
malignancies; long-term use of steroids; severe pneu-
monia; 12-lead electrocardiogram that shows abnormal
cardiac conduction or QT interval prolongation (male,
QTc > 430 milliseconds; female, QTc > 450 milliseconds);
treatment with chemotherapeutic drugs or oncolytics
within 6 months before randomization or requiring such
agents during the trial; alcohol or drug abuse; adminis-
tration of any quinolone within 2 weeks before randomi-
zation; received any investigational drug within 3 months
before enrollment; donation of 500 mL of blood within
3 months; or requiring combined antimicrobial therapy
because of dual infection.
Primary and secondary endpoints
Clinical response at the test of cure (TOC) visit (i.e.,
7e10 days posttreatment) was the primary efficacy
endpoint of this study. Cinical efficacy was defined as
“clinical cure” (i.e., complete resolution of all signs and
symptoms of pneumonia, or recovery to the pretreatment
state); as “clinical failure” (i.e., persistence or worsening
of signs and symptoms after therapy, or the emergence oflind, multicenter Phase II study comparing the efficacy and safety
ity-acquired pneumonia, Journal of Microbiology, Immunology and
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+ MODELnew pneumonia-related symptoms or signs and/or use of
other antimicrobial therapy targeting pneumonia; or
discontinuation within 3 days after the initiation of study
treatment because of an adverse drug reaction); or as
“unevaluable” (e.g., missing posttreatment information,
use of systemic antimicrobial agents for other indications
not permitted by protocol, or early discontinuation of
treatment because of other causes unrelated to the study
drug).
Secondary endpoints included clinical and bacteriolog-
ical response at the end of treatment in the full analysis set
(FAS) and per protocol set and at the TOC in the per pro-
tocol set.
Microbiological assessment
Before the first dose of study drug, sputum samples were
collected by every reasonable effort for Gram stain and
culture. Atypical pathogens were identified by serological
assay. Microbiological response was categorized as “eradi-
cation” (i.e., the original pathogens were absent at the
TOC visit), “presumed eradication” (i.e., the patient was
considered clinically cured but a repeat sputum/blood
culture was absent), and “persistence” (i.e., the original
pathogens persisted at the TOC visit), and “presumed
persistence” (i.e., the patient still had clinical signs and
symptoms but a repeat sputum culture was absent). Anti-
microbial susceptibility test of nemonoxacin and levo-
floxacin was performed by microdilution assay, based on
Clinical and Laboratory Standard Institute document M100-
S21 (2011). Only patients with positive admission cultures
were included in the bacteriological response analysis.
Comprehensive efficacy assessment
Clinically evaluable patients with positive bacterial culture
at baseline were included for comprehensive assessment.
The clinical signs and symptoms, radiologic and laboratory
tests, and microbiological examination were combined to
evaluate the comprehensive efficacy. Comprehensive
response was categorized as “cure” (i.e., at the TOC visit,
the clinical response was cure and the microbiological
response was eradication or presumed eradication) and
“failure” (i.e., at the TOC visit, the clinical response was
failure or the microbiological response was persistence or
presumed persistence). Comprehensive efficacy was eval-
uated as “failure” if one clinical or microbiological
response was a failure and another response was missing,
and evaluated as “unknown” if one clinical or microbio-
logical response was cure/presumed eradication and the
other response was missing.
Safety assessment
All clinical and laboratory adverse events that occurred
during clinical trial were carefully observed and recorded
for all patients who received at least one dose of the study
drug. The adverse events were categorized as “definitely
related,” “probably related,” “possibly related,” “possibly
unrelated” or “definitely unrelated,” based on their rela-
tion to the study drug.Please cite this article in press as: Liu Y, et al., A randomized, double-b
of oral nemonoxacin with oral levofloxacin in the treatment of commun
Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.09.005Patient populations
The following five patient populations were defined in this
study for the analysis of clinical and microbiological
efficacy.
(1) Full analysis set (FAS): all patients were included in the
full analysis set, except for patients who did not
receive any study drug, did not have the target disease,
were noncompliantwith good clinical practice, orwere
missing follow-up information after the first visit.
(2) Per protocol set (PPS): all patients in the FAS were
included in the per protocol set, except for patients
inadequately enrolled with an exclusion criterion;
patients who required treatment by other effective
antibiotics, but not patients who were evaluated as a
failure at the end of treatment and then received
other antibiotic therapy; or noncompliant patients,
as evidenced by taking < 80% or > 120% of the in-
dividual’s prescribed dose.
The FAS and PPS were applicable for efficacy analysis.
Clinical response at the TOC visit in FAS was the primary
efficacy endpoint of this study.
(3) Safety set (SS): all patients who received at least one
dose of the study drug were included in the SS. The SS
was applicable for safety analysis.
(4) Bacteriological full analysis set (BFAS): all patients in
the FAS whose first sputum culture or blood culture
was positive were included.
(5) Bacteriological per protocol set (BPPS): all patients in
the PPS whose first sputum culture or blood culture
was positive were included.Statistical analysis
SAS 9.1.3 software (North Carolina, USA) was used for all
statistical analysis. Noninferiority was defined as the lower
limit of the 95% confidence interval (CI) for the difference
between groups being greater than 15%. In addition to
noninferiority analysis, two-sided exact 95% CI was used to
compare the difference of clinical success rates between
treatment groups.Results
Patient disposition
One hundred and ninety-two patients were randomized in
this study from 21 centers in China: 168 patients who
received at least one dose of the study drug in the FAS (60
patients in the nemonoxacin 500 mg group, 56 patients in
the nemonoxacin 750 mg group, and 52 patients in the
levofloxacin group); 152 patients in the PPS (57 patients in
the nemonoxacin 500 mg group, 50 patients in the nem-
onoxacin 750 mg group, and 45 patients in the levofloxacin
group); 177 patients in the SS (62 patients in the nem-
onoxacin 500 mg group, 59 patients in the nemonoxacinlind, multicenter Phase II study comparing the efficacy and safety
ity-acquired pneumonia, Journal of Microbiology, Immunology and
Figure 1. Patient disposition flow chart. BFAS Z bacteriological full analysis set; BPPS Z bacteriological per protocol set;
FAS Z full analysis set; LEVO Z levofloxacin; NEMO Z nemonoxacin; PPS Z per protocol set; SS Z safety set.
Table 1 Clinical response at the test of cure visit
Nemonoxacin
500 mg
N (%)
Nemonoxacin
750 mg
N (%)
Levofloxacin
500 mg
N (%)
Full analysis set
Clinical cure 56 (93.3) 48 (87.3) 46 (88.5)
Clinical failure 4 (6.7) 7 (12.7) 6 (11.5)
Unevaluable 0 1 0
Per protocol set
Clinical cure 53 (93.0%) 46 (93.9%) 40 (88.9%)
Clinical failure 4 (7.0%) 3 (6.1%) 5 (11.1%)
Unevaluablea 0 1 0
a Unevaluable cases are not included in the denominator.
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There were 57 patients in the BFAS and 50 patients in the
BPPS (Figure 1).
Demographic characteristics such as age, sex, race,
height, weight, BMI, history of smoking and drinking were
comparable between the three treatment groups. The
mean age of the patients was 38.5  14.4 years in the
nemonoxacin 500 mg group, 38.3  15.4 years in the
nemonoxacin 750 mg group, and 39.7  15.1 years in the
levofloxacin 500 mg group. The mean BMI was
22.5  3.6 kg/m2 in the nemonoxacin 500 mg group,
22.6  3.0 kg/m2 in the nemonoxacin 750 mg group, and
22.2  3.4 kg/m2 in the levofloxacin 500 mg group. Most
patients had no history of smoking (85.7e93.3%) or drinking
(76.9e83.9%).
Underlying diseases
The most common underlying disease was hypertension
(5.0e7.1%), followed by diabetes mellitus (0e5.4%),
tuberculosis (1.8e3.3%), and chronic bronchitis (1.7e3.6%).
There was no significant difference between the three
groups with regard to underlying diseases in the FAS.
Dose and duration
In the FAS, the mean duration of therapy was 9.4  1.3 days
in the nemonoxacin 500 mg group, 9.2  1.9 days in the
nemonoxacin 750 mg group, and 9.4  1.7 days in the lev-
ofloxacin 500 mg group. The mean total dose administered
during the study was 4708.3  619.5 mg in the nemonoxacinPlease cite this article in press as: Liu Y, et al., A randomized, double-b
of oral nemonoxacin with oral levofloxacin in the treatment of commun
Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.09.005500 mg group, 6910.7  1428.2 mg in the nemonoxacin
750 mg group, and 4682.7  851.9 mg in the levofloxacin
500 mg group.Clinical efficacy
The clinical primary efficacy variable was evaluated at the
TOC visit in the FAS of this study. The clinical cure rate at
the TOC in the FAS population was 93.3% in the nemonox-
acin 500 mg group, 87.3% in the nemonoxacin 750 mg group,
and 88.5% in the levofloxacin 500 mg group (Table 1). No
significant difference existed between these three treat-
ment groups. The 95% CI for the treatment difference
(4.9%) between the nemonoxacin 500 mg and levofloxacinlind, multicenter Phase II study comparing the efficacy and safety
ity-acquired pneumonia, Journal of Microbiology, Immunology and
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95% CI for the treatment difference (1.2%) between the
nemonoxacin 750 mg and levofloxacin 500 mg groups ranged
from 13.56% to 11.18%. The treatment efficacy of either
500 mg or 750 mg of nemonoxacin was noninferior to that of
levofloxacin 500 mg in the FAS population because the
lower limit of 95% CI of the treatment difference was
greater than 15%. The noninferiority of nemonoxacin at
500 mg or 750 mg to levofloxacin at 500 mg was demon-
strated in the treatment of adult CAP patients.
The PPS population at the TOC visit also showed no
significant difference between these three treatment
groups (Tables 1 and 2).
Logistic regression analysis showed no significant dif-
ference in clinical efficacy between nemonoxacin 500 mg,
nemonoxacin 750 mg, and levofloxacin 500 mg groups in the
FAS and PPS populations (p > 0.05; Table 3).
Clinical response was also assessed at the TOC visit in
terms of primary baseline pathogens, which were identified
in 90 (53.6%) of the 168 patients in the FAS (Table 4). Sixty-
one strains of bacteria were isolated from 57 patients, and
33 atypical pathogens were identified serologically. All
patients with S. pneumoniae isolates (n Z 11) or S. aureus
isolates (nZ 4) were cured in the three groups, except for
treatment failure in one patient with the S. pneumoniae
isolate in the levofloxacin 500 mg group. Of the 18 patients
infected with H. influenzae, 15 patients were cured, but
there were treatment failures in each of the three groups.
One patient in the nemonoxacin 750 mg group and two
patients in the levofloxacin 500 mg group who were infec-
ted with K. pneumoniae were evaluated as treatment
failure. The remaining 13 patients with the K. pneumoniae
isolate at baseline were cured. Thirty-three patients in the
FAS were infected with only atypical pathogens, which
included M. pneumoniae (n Z 29), Chlamydia pneumoniae
(n Z 1), and Legionella pneumophila (n Z 3). Treatment
failure was determined for one patient with single M.
pneumoniae infection in the nemonoxacin 750 mg group.
The other 32 patients with atypical pathogen infection
were cured.Bacteriological efficacy
The bacteriological primary efficacy was evaluated at the
TOC visit in the BFAS in this study. Sixty-one pathogensTable 2 Clinical efficacy and treatment difference between th
Levofloxacin
500 mg
Nemonoxacin
500 mg
N (%) N (%) Treatment
Difference (%)
p (95% CI
Full analysis
set
46 (88.5) 56 (93.3) 4.9 0.569 (5
Per protocol
set
40 (88.9) 53 (93.0) 4.1 0.851 (7
CI Z confidence interval.
Treatment difference Z nemonoxacin group e levofloxacin.group.
Please cite this article in press as: Liu Y, et al., A randomized, double-b
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Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.09.005were isolated at baseline from 57 patients in the BFAS
population, and included 20 strains in the nemonoxacin
500 mg group, 19 strains in the nemonoxacin 750 mg group
and 22 strains in the levofloxacin 500 mg group. The
bacteriological response at the TOC visit in the BFAS and
BPPS populations is presented by the treatment group in
Table 5.
The bacteriological success rate for the bacteriological
evaluable set was 83.3% (15/18) (in the nemonoxacin
500 mg group and nemonoxacin 750 mg group) and 80.0%
(16/20) in the levofloxacin 500 mg group. There was no
significant difference between the three treatment groups,
based on logistic regression analysis.
The most common pathogens among the 61 pathogens
isolated at baseline were S. pneumoniae, H. influenza, and
K. pneumoniae, followed by some strains of S. aureus
(including MRSA) and Pseudomonas aeruginosa. At the TOC
visit, all baseline strains were eradicated in the nemonox-
acin 500 mg and 750 mg groups: S. pneumoniae (6 strains),
S. aureus (including MRSA, 4 strains), and H. influenzae (5
strains). The K. pneumoniae and P. aeruginosa strains were
eradicated, except one strain each in the nemonoxacin
750 mg group. All baseline isolates in the levofloxacin
500 mg group were eradicated, except one S. pneumoniae
strain, one H. influenzae strain, and two K. pneumoniae
strains.
All the common respiratory pathogens isolated from this
study including S. pneumoniae and H. influenzae were
susceptible to nemonoxacin and levofloxacin (Table 6).
Staphylococcus aureus including three MRSA strains were
also sensitive to nemonoxacin.Comprehensive efficacy
The comprehensive efficacy was evaluated in terms of
clinical and bacteriological efficacy at the TOC visit in the
BPPS population of this study. Fifty patients were included
for the assessment of comprehensive efficacy, which
included 17 patients each in the nemonoxacin 500 mg and
750 mg groups and 16 patients in the levofloxacin 500 mg
group. The comprehensive success rate at the TOC in the
BPPS population was 87.5% in the nemonoxacin 500 mg
group, 93.8% in the nemonoxacin 750 mg group, and 81.3%
in the levofloxacin 500 mg group. Logistic regressione three groups at the test of cure visit
Nemonoxacin 750 mg
) N (%) Treatment
Difference (%)
p (95% CI)
.86, 15.61) 48 (87.3) 1.2 0.71 (13.56, 11.18)
.23, 15.42) 46 (93.9) 5.0 0.62 (6.39, 16.36)
lind, multicenter Phase II study comparing the efficacy and safety
ity-acquired pneumonia, Journal of Microbiology, Immunology and
Table 3 Logistic regression analysis of the efficacy of nemonoxacin treatments compared with levofloxacin at the test of cure
visit
Nemonoxacin 500 mg Nemonoxacin 750 mg
OR 95% CI Wald c2 p OR 95% CI Wald c2 p
Full analysis set 1.83 (0.49, 6.86) 0.7947 0.3727 0.89 (0.28, 2.86) 0.0354 0.8508
Per protocol set 1.66 (0.42, 6.57) 0.5155 0.4728 1.92 (0.43, 8.53) 0.7297 0.3930
CI Z confidence interval; OR, the ratio between nemonoxacin treatment and levofloxacin in the clinical efficacy rate.
Table 4 Clinical efficacy at the test of cure visit by primary baseline pathogens in the full analysis set
Pathogen Number of isolates Nemonoxacin 500 mg Nemonoxacin 750 mg Levofloxacin 500 mg
n1/n2 (%)a n1/n2 (%)a n1/n2 (%)a
Typical pathogen
Streptococcus. pneumoniae 11 2/2 (100) 4/4 (100)b 3/4 (75.0)
Staphylococcus aureusc 4 2/2 (100) 2/2 (100) 0/0
Haemophilus influenzae 9 3/3 (100) 2/2 (100) 3/4 (75.0)
Haemophilus parainfluenzae 9 2/3 (66.7) 3/4 (75.0) 2/2 (100)
Klebsiella pneumoniae 16 4/4 (100) 2/3 (66.7) 7/9 (77.8)
Atypical pathogen only
Mycoplasma pneumoniae 29 7/7 (100) 13/14 (92.9) 8/8 (100)
Legionella pneumophila 3 2/2 (100) 0/0 1/1 (100)
Chlamydia pneumoniae 1 0/0 1/1 (100) 0/0
a n1 Z the number of clinical cure; n2 Z total number of the patients treated.
b There were five Streptococcus pneumoniae isolates at the end of treatment. One strain was unevaluable because the patient
received acetylspiramycin before the test of cure visit.
c Among the four Staphylococcus aureus isolates, three isolates are methicillin-resistant: two isolates are in the nemonoxacin 500 mg
group and one isolate is in the nemonoxacin 750 mg group.
Table 5 Bacteriological efficacy at the test of cure visit by treatment group
Nemonoxacin 500 mg
N (%)
Nemonoxacin 750 mg
N (%)
Levofloxacin 500 mg
N (%)
Bacteriological full analysis set a
Bacteriological successb 15 (83.3) 15 (83.3) 16 (80.0)
Bacteriological failurec 3 (16.7) 3 (16.7) 4 (20.0)
Unevaluable 0 1 0
Bacteriological per protocol set
Bacteriological success 14 (82.4) 15 (93.8) 13 (81.3)
Bacteriological failure 3 (17.7) 1 (6.2) 3 (18.7)
Unevaluable 0 1 0
a Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila are not included.
b Bacteriological success includes eradication and presumed eradication.
c Bacteriological failure includes persistence, presumed persistence, and partial eradication.
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three treatment groups.
Safety and tolerability
One hundred and seventy-seven patients who received at
least one dose of the study drug were included in the SS
population. Sixty-two patients received 500 mg of nem-
onoxacin, 59 patients received 750 mg of nemonoxacin, and
56 patients received 500 mg of levofloxacin. The incidencePlease cite this article in press as: Liu Y, et al., A randomized, double-b
of oral nemonoxacin with oral levofloxacin in the treatment of commun
Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.09.005of treatment emergent adverse events (TEAEs) was 41.9% in
the nemonoxacin 500 mg group, 55.9% in the nemonoxacin
750 mg group, and 42.9% in the levofloxacin 500 mg group
(Table 7). The incidence of drug-related TEAEs was similar
between the nemonoxacin 500 mg, nemonoxacin 750 mg,
and levofloxacin 500 mg groups at 30.6%, 35.6%, and 25.0%,
respectively (p > 0.05).
Twenty-eight drug-related TEAEs occurred in 19 patients
in the nemonoxacin 500 mg group: three clinical adverse
events (AEs; primarily anorexia, nausea, and epigastriclind, multicenter Phase II study comparing the efficacy and safety
ity-acquired pneumonia, Journal of Microbiology, Immunology and
Table 6 In vitro susceptibilities of primary baseline isolates to the study drugs
Bacteria (n) Nemonoxacin Levofloxacin
MIC range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
MIC range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
Streptococcus pneumoniaea (13) 0.015e1 0.125 0.25 0.03e1 0.25 0.5
Staphylococcus aureusb (4) 0.06e1 0.125e32
Klebsiella pneumoniae (19) 0.06e>32 0.5 32 0.06e>32 0.125 >32
Haemophilus influenzae and
Haemophilus parainfluenzae (16)
0.008e1 0.06 1 0.008e1 0.06 1
a Thirteen Streptococcus pneumoniae strains were isolated from all randomized groups. Two strains are excluded from the bacteri-
ological full analysis set because the patient took the wrong drugs.
b The MIC50 and MIC90 were not calculated because of the few number of strains.
MICZ minimal inhibitory concentration; MIC50/MIC90 Z the lowest concentration of an antibiotic at which 50% and 90% of the isolates
are inhibited.
Table 7 Summary of the most common treatment-related adverse events (2% in any one group) by system organ and
preferred term
System organ class and preferred term Nemonoxacin 500 mg Nemonoxacin 750 mg Levofloxacin 500 mg
(N Z 62) (N Z 59) (N Z 56)
n (%) n (%) n (%)
Patients with any treatment-related adverse event 19 (30.6) 21 (35.6) 14 (25.0)
Digestive system
Nausea 1 (1.6) 6 (10.2) 1 (1.8)
Vomiting 0 4 (6.8) 2 (3.6)
Stomach upset 0 2 (3.4) 1 (1.8)
Blood and lymphatic system
Leukopenia 4 (6.5) 6 (10.2) 4 (7.1)
Neutropenia 2 (3.2) 2 (3.4) 2 (3.6)
Percentage of eosinophils increased 2 (3.2) 1 (1.7) 0
Percentage of neutrophils increased 1 (1.6) 2 (3.4) 1 (1.8)
Abnormal Laboratory Value
Abnormal liver function 0 3 (5.1) 0
Elevated alanine aminotransferase 3 (4.8) 0 1 (1.8)
Elevated urinary protein 0 1 (1.7) 2 (3.6)
Cardiovascular system
QT interval prolongation 2 (3.2) 3 (5.1) 1 (1.8)
Bundle branch block 2 (3.2) 0 0
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+ MODELdiscomfort) in three (4.8%) patients and 25 episodes of
laboratory abnormalities (primarily leukopenia and
elevated alanine aminotransferase level) in 16 (25.8%) pa-
tients. No patient had both drug-related adverse and lab-
oratory abnormalities.
Forty-three drug-related TEAEs occurred in 21 subjects
in the nemonoxacin 750 mg group: 22 clinical AEs in 12
(20.3%) patients and 21 episodes of laboratory abnormal-
ities in 13 (22.0%) patients. The most common drug-related
TEAEs (2%) were nausea, vomiting, leucopenia, and
abnormal liver function. Four patients experienced both
clinical AEs and laboratory abnormalities during the study.
Twenty-four drug-related TEAEs occurred in 14 patients
in the levofloxacin 500 mg group: eight clinical AEs in five
(8.9%) patients and 16 episodes of laboratory abnormalities
in 11 (19.6%) patients. The most common drug-related
TEAEs (2%) were nausea, vomiting, leukopenia,Please cite this article in press as: Liu Y, et al., A randomized, double-b
of oral nemonoxacin with oral levofloxacin in the treatment of commun
Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.09.005neutropenia, and elevated urinary protein. Two patients
experienced both clinical AEs and laboratory abnormalities
during the study.
Drug-related QT interval prolongation occurred in all
three treatment groups: 3.2% (n Z 2) in the nemonoxacin
500 mg group, 5.1% (n Z 3) in the nemonoxacin 750 mg
group, and 1.8% (n Z 1) in the levofloxacin 500 mg group.
Prolongation of the QT interval was shorter than 30 milli-
seconds in all patients, except in one female patient in the
nemonoxacin 750 mg group (557 milliseconds). There were
two (3.2%) cases of drug-related cardiac bundle branch
block in the nemonoxacin 500 mg group, and one case of
drug-related ventricular premature beats in the levo-
floxacin 500 mg group.
Drug-related TEAEs were mild to moderate, and >90%
of TEAEs were mild. The proportion of AEs classified as
mild was 96.4% in the nemonoxacin 500 mg group, 93.0% inlind, multicenter Phase II study comparing the efficacy and safety
ity-acquired pneumonia, Journal of Microbiology, Immunology and
Nemonoxacin versus levofloxacin in treating CAP 9
+ MODELthe nemonoxacin 750 mg, and 92.0% in the levofloxacin
500 mg. Only one patient in the nemonoxacin 750 mg
group experienced facial twitch, which resulted in the
discontinuation of the study drug. This symptom dis-
appeared quickly after discontinuation of the study drug.
No drug-related serious adverse event was observed in this
study.Discussion
This study demonstrated that oral nemonoxacin at 500 mg
or 750 mg, administered once daily for 7e10 days, achieved
excellent clinical and microbiological efficacy in the
treatment of CAP in Chinese adults. Both doses (i.e.,
500 mg and 750 mg) of nemonoxacin were noninferior to
levofloxacin (500 mg) for the treatment of adult CAP in
primary efficacy at the TOC visit in the FAS population. The
microbiological efficacy or bacteriological eradication rate
was comparable between the nemonoxacin and levo-
floxacin regimens.
Our results prove that nemonoxacin is highly active with
broad-spectrum activity against major CAP pathogens. Pa-
tients with CAP who were infected with S. pneumoniae, H.
influenzae, M. pneumoniae, C. pneumoniae, or L. pneu-
mophila were all cured clinically at the TOC visit. Three of
the four S. aureus isolates at baseline were MRSA, and all
isolates were obtained from the nemonoxacin treatment
group patients. All patients with S. aureus infection were
successfully cured. The excellent clinical and bacteriolog-
ical efficacy suggests good activity of nemonoxacin against
these resistant strains, although the number of patients
with MRSA was fewer. In vitro studies have shown that
nemonoxacin had good activity against gram-positive bac-
teria such as MRSA.16,17
In this trial, nemonoxacin was well tolerated in both
treatment groups. More than 93% of the drug-related TEAEs
were mild. Only one patient discontinued the study drug
because of a TEAE. Drug-related TEAEs were primarily mild
gastrointestinal disorders, transient leucopenia, and
elevated liver enzymes. The incidence of drug-related
TEAEs in the present study was similar to that reported in
a South African Phase II clinical trial in which the incidence
of AEs was 30.3% in the nemonoxacin 500 mg group, 31.4%
in the nemonoxacin 750 mg group, and 30.0% in the levo-
floxacin 500 mg group. The most common AEs in the South
African study were mild gastrointestinal disorders and
transient neutropenia.15
The overall incidence of drug-related TEAEs in the
nemonoxacin 750 mg group (35.6%) was slightly higher than
the incidence in the nemonoxacin 500 mg group (30.6%).
These findings suggest that the nemonoxacin 500 mg
treatment regimen may be safer than the 750 mg regimen
in treating adult CAP. In future Phase III clinical trials, the
nemonoxacin 500 mg regimen is recommended, based on its
similar efficacy and better safety profile in comparison to
the 750 mg regimen.
In summary, 500 mg or 750 mg of oral nemonoxacin
administered once daily for 7e10 days showed good clinical
and microbiological efficacy in treating adult CAP. Either
500 mg or 750 mg nemonoxacin once daily was proven as
noninferior to 500 mg levofloxacin at the TOC visit, andPlease cite this article in press as: Liu Y, et al., A randomized, double-b
of oral nemonoxacin with oral levofloxacin in the treatment of commun
Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.09.005both regimens were well tolerated. The incidence of drug-
related TEAEs was slightly higher in the nemonoxacin
750 mg group than in the nemonoxacin 500 mg group, but
the difference was not significant. Based on the afore-
mentioned results, 500 mg of nemonoxacin administered
once daily for 7e10 days is recommended for future Phase
III clinical trials.
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